A Cell-Free DNA Plasma Next-Generation Sequencing Test—Is It Worth the Cost?
The KT demonstrates modest clinical utility with noteworthy benefits in select scenarios. Given its high cost and variable impact, we advocate for diagnostic stewardship led by infectious disease specialists to optimize test use and minimize unnecessary expense.
Authors
- Sang‐Hun Jung (ORCID: https://orcid.org/0000-0001-9629-3685)
- Francesca J. Torriani (ORCID: https://orcid.org/0000-0001-8389-8589)
- Shira R. Abeles (ORCID: https://orcid.org/0000-0003-3635-2019)
- Ahnika Kline
Institutions
- University of California System (US)
- University of California San Diego (US)
Publication Details
- Journal
- Pathogens
- Published
- 2025-08-15
- DOI
- https://doi.org/10.3390/pathogens14080811
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institutes of Health
- University of California, San Diego